Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Free Cash Flow
Sonoma Pharmaceuticals Inc
Free Cash Flow Peer Comparison
Competitive Free Cash Flow Analysis
Latest Figures & CAGR of Competitors
Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Free Cash Flow
-$5.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
16%
|
CAGR 10-Years
0%
|
|
Johnson & Johnson
NYSE:JNJ
|
Free Cash Flow
$18.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Free Cash Flow
$12.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Free Cash Flow
$5.1B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Merck & Co Inc
NYSE:MRK
|
Free Cash Flow
$11B
|
CAGR 3-Years
18%
|
CAGR 5-Years
6%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Free Cash Flow
-$3.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Sonoma Pharmaceuticals Inc's Free Cash Flow?
Free Cash Flow
-5.2m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Free Cash Flow amounts to -5.2m USD.
What is Sonoma Pharmaceuticals Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
0%
Over the last year, the Free Cash Flow growth was 1%. The average annual Free Cash Flow growth rates for Sonoma Pharmaceuticals Inc have been 3% over the past three years , 16% over the past five years .